STERIS (NYSE:STE) Issues FY25 Earnings Guidance

STERIS (NYSE:STE) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $9.05-$9.25 for the period, compared to the consensus estimate of $9.16. STERIS also updated its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Stock Up 0.0 %

Shares of STERIS stock traded up $0.08 during trading on Wednesday, hitting $227.52. 1,402,169 shares of the stock traded hands, compared to its average volume of 483,986. The stock has a market cap of $22.44 billion, a P/E ratio of 56.44 and a beta of 0.85. The company has a fifty day moving average price of $233.36 and a two-hundred day moving average price of $227.60. STERIS has a twelve month low of $195.47 and a twelve month high of $248.24. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. STERIS’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm earned $2.00 EPS. Equities research analysts predict that STERIS will post 9.02 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.00%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s dividend payout ratio is 56.58%.

Analyst Ratings Changes

A number of research firms have recently commented on STE. KeyCorp lifted their price target on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price target for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Stephens reaffirmed an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. Finally, JMP Securities reissued a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.00.

Insider Buying and Selling at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other STERIS news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the transaction, the director now owns 582 shares of the company’s stock, valued at approximately $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.